Table 4 Baseline levels and overtime variations in IL-6 and SOFA score in patients treated with tocilizumab and/or lopinavir-ritornavir
|  | n (%) | Baseline SOFA score | Baseline IL-6 | Δ SOFA score at 24 h | Δ IL-6 at 24 h | Mortality rate | |
|---|---|---|---|---|---|---|---|
Tocilizumab |  | 15 (40.5%) | 13 (IQR 3.5) | 1598 (IQR 1635)* | − 1 (IQR − 2.3) | − 642 (IQR − 548) | 8 (53.3%) |
Lop_Rit | 2 (5.4%) | 13 (IQR 2) | 1125 (IQR 275) | − 4.00 (IQR 0)§ | − 571 (IQR −71) | 1 (50.0%) | |
No-Lop_Rit | 13 (35.1%) | 13 (IQR 3) | 1753 (IQR 1933) | − 0.50 (IQR − 1)§ | − 904 (IQR − 631) | 7 (53.8%) | |
No-Tocilizumab |  | 22 (59.5%) | 13 (IQR 7.8) | 1089 (IQR 67)* | 0 (IQR − 1) | − 552 (IQR − 526) | 13 (59.1%) |
Lop_Rit | 7 (18.9%) | 14 (IQR 5.5) | 1180 (IQR 80) | − 1 (IQR − 2) | − 702 (IQR − 15) | 3 (42.9%) | |
No-Lop_Rit | 15 (40.5%) | 13 (IQR 8.5) | 794 (IQR 607) | 0 (IQR − 1) | − 401 (IQR − 601) | 10 (66.7%) | |